Role of the host tissue in the anti-invasive activity of the alkyllysophospholipid, ET-18-OCH3, in vitro.
The alkyllysophospholipid, racemic-l-O-octadecyl-2-O-methylglycero-3- phosphocholine (ET-18-OCH3) was previously shown to inhibit invasion of malignant cells into precultured heart fragments (PHF) in vitro. In particular, pretreatment of PHF with 10 micrograms ET-18-OCH3 for 48 h was sufficient to induce in the host tissue resistance towards invasion by mouse MO4 cells. Resistance was obvious when MO4 cells were confronted either immediately (the pretreatment experiment) or after withdrawal of the drug 7 days prior to confrontation (the reversibility experiment). In the present study, the survival of PHF cells in the pretreatment and reversibility experiments was similar to that of untreated PHF cells as determined by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) test and by the PHF explantation test. The effective anti-invasive concentration was 6 micrograms/ml in the pretreatment experiment while 3 micrograms/ml was sufficient to inhibit invasion in the reversibility experiment. Induction of resistance towards invasion in pretreated PHF was shown to occur not only with MO4 cells but also with mouse LLC-H61 Lewis lung carcinoma and mouse BW-O-Li1 T-lymphoma cells. The increase in molecular weight of N-linked cell surface glycosylpeptides (N-GP) of PHF was apparent in the pretreatment experiment and was enhanced in the reversibility experiment. This effect was completely abolished in cells obtained from pretreated PHF which were converted into a cell suspension and further cultured as a monolayer on tissue culture plastic without drug for 7 days. The results reported here provide additional evidence for the causal involvement of N-GP of the PHF host tissue in the anti-invasive activity of ET-18-OCH3 in vitro.
Schallier
D C
DC
Department of Radiotherapy and Nuclear Medicine, University Hospital, Ghent, Belgium.
Bruyneel
E A
EA
Storme
G A
GA
Mareel
M M
MM
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D006020:Glycopeptides / Q000302:isolation & purification; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D006338:Heart Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000473:pathology*; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000473:pathology*; D051379:Mice; D009206:Myocardium / Q000737:chemistry; D009361:Neoplasm Invasiveness / Q000473:pathology; D009363:Neoplasm Proteins / Q000302:isolation & purification; D009924:Organ Culture Techniques; D010742:Phospholipid Ethers / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D006020:Glycopeptides; D009363:Neoplasm Proteins; D010742:Phospholipid Ethers; C026659:edelfosine